P/E ratio for Galectin Therapeutics (GALT)
P/E ratio as of May 2024 (TTM): -4.76
According to Galectin Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.75758. At the end of 2022 the company had a P/E ratio of -1.74.
P/E ratio history for Galectin Therapeutics from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.74 | -56.33% |
| 2021 | -3.98 | -28.91% |
| 2020 | -5.60 | -15.8% |
| 2019 | -6.65 | -26.31% |
| 2018 | -9.03 | 32.42% |
| 2017 | -6.82 | 428.61% |
| 2016 | -1.29 | -30.81% |
| 2015 | -1.86 | -57.57% |
| 2014 | -4.39 | -28.79% |
| 2013 | -6.17 | 116.63% |
| 2012 | -2.85 | -47.6% |
| 2011 | -5.43 | -0.38% |
| 2010 | -5.45 | 289.61% |
| 2009 | -1.40 | 24.44% |
| 2008 | -1.13 | -59.82% |
| 2007 | -2.80 | -31.56% |
| 2006 | -4.09 | -69.15% |
| 2005 | -13.3 | 53.83% |
| 2004 | -8.62 | -58.53% |
| 2003 | -20.8 | 57.71% |
| 2002 | -13.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Mirati Therapeutics MRTX | -4.58 | -3.76% | 🇺🇸 USA |
 MannKind Corp MNKD | -24.2 | 407.78% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.